Overview
Aggrecan-related bone disorder is a group of skeletal conditions caused by changes (mutations) in the ACAN gene, which provides instructions for making a protein called aggrecan. Aggrecan is a major building block of cartilage — the tough, flexible tissue that cushions joints and forms the framework for bones to grow during childhood. When this protein does not work properly, it can lead to problems with bone growth and joint health. Note: This specific Orphanet entry (364817) is labeled as 'OBSOLETE,' meaning it has been retired and replaced by more specific disease classifications. The conditions previously grouped under this term have been reclassified into distinct diagnoses, including spondyloepiphyseal dysplasia (aggrecan type), short stature with advanced bone age, and familial osteochondritis dissecans. Patients who were previously given this diagnosis should work with their geneticist to determine which updated classification best fits their condition. Common features across aggrecan-related bone disorders include short stature, early-onset joint problems (such as osteoarthritis), and abnormalities in the growth plates of bones. Some individuals may also experience midface flattening and early maturation of the skeleton (advanced bone age). The severity can vary widely, even within the same family. Treatment is generally supportive and may include growth hormone therapy for short stature, pain management, physical therapy, and orthopedic interventions for joint problems. There is currently no cure that addresses the underlying genetic cause.
Key symptoms:
Short stature or being shorter than expectedEarly-onset arthritis or joint painJoint stiffnessAdvanced bone age on X-raysBroad, short fingersFlat midface appearanceEarly wear and tear of joint cartilageBack pain or spinal problemsOsteochondritis dissecans (pieces of cartilage breaking off in joints)Difficulty with physical activities due to joint problemsBarrel-shaped chest in some casesDisc problems in the spine
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Aggrecan-related bone disorder.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for OBSOLETE: Aggrecan-related bone disorder at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Aggrecan-related bone disorder.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Aggrecan-related bone disorder.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Aggrecan-related bone disorder.
Start the conversation →Latest news about OBSOLETE: Aggrecan-related bone disorder
No recent news articles for OBSOLETE: Aggrecan-related bone disorder.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which specific type of aggrecan-related bone disorder does my child have, given that the original classification is now obsolete?,Would growth hormone therapy be beneficial, and what results can we realistically expect?,How often should we have X-rays or other imaging to monitor bone and joint health?,What types of physical activities are safe, and which should be avoided?,At what point should we consider orthopedic surgery for joint problems?,Should other family members be tested for the ACAN gene mutation?,Are there any clinical trials or new treatments being studied for this condition?
Common questions about OBSOLETE: Aggrecan-related bone disorder
What is OBSOLETE: Aggrecan-related bone disorder?
Aggrecan-related bone disorder is a group of skeletal conditions caused by changes (mutations) in the ACAN gene, which provides instructions for making a protein called aggrecan. Aggrecan is a major building block of cartilage — the tough, flexible tissue that cushions joints and forms the framework for bones to grow during childhood. When this protein does not work properly, it can lead to problems with bone growth and joint health. Note: This specific Orphanet entry (364817) is labeled as 'OBSOLETE,' meaning it has been retired and replaced by more specific disease classifications. The cond
How is OBSOLETE: Aggrecan-related bone disorder inherited?
OBSOLETE: Aggrecan-related bone disorder follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does OBSOLETE: Aggrecan-related bone disorder typically begin?
Typical onset of OBSOLETE: Aggrecan-related bone disorder is childhood. Age of onset can vary across affected individuals.